Truist Securities raised the price target for Corcept Therapeutics Incorporated CORT and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it "is impressive and difficult to ignore." Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who ca ...

Corcept Therapeutics (CORT) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 15.7% gain over the past four weeks. The company's sole marketed drug, Korlym, approved for treating Cushing's syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing's syndrome is expected to be filed in ...

Shares of Corcept Therapeutics Incorporated (CORT) have gained 46.2% in the past six months against the industry's decline of 2%. The company's sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome, has been performing well. The drug has been witnessing a strong demand in the past couple of quarters. The company is also making good progress with its promising set of pipeline candidates. Factors Driving CORT Stock in the Given Time Frame Corcept has made steady progress ...

Investors might want to bet on Corcept Therapeutics (CORT) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. S ...

NEW YORK, Aug. 26, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Corcept Therapeutics Incorporated (NASDAQ: CORT) on behalf of the company's shareholders. The investigation seeks to determine whether Corcept's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Corcept Therapeutics Incorporated and are interested in obtaining additional information regarding your rights and options, free of charge, please visit ...

Corcept Therapeutics (CORT) closed the last trading session at $34.94, gaining 5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $59.60 indicates a 70.6% upside potential. The average comprises five short-term price targets ranging from a low of $38 to a high of $78, with a standard deviation of $17.33. While the lowest estimate indicates an increase of 8.8% from the current price ...

Have you been paying attention to shares of Corcept Therapeutics (CORT) ? Shares have been on the move with the stock up 26.8% over the past month. The stock hit a new 52-week high of $39.75 in the previous session. Corcept Therapeutics has gained 19.1% since the start of the year compared to the 7.1% move for the Zacks Medical sector and the -1.9% return for the Zacks Medical - Drugs industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't misse ...

Corcept Therapeutics (CORT) could be a solid addition to your portfolio given a notable revision in the company's earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this drug developer, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings esti ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Eve ...

Corcept Therapeutics Overview For some background: The conflict between Corcept and Teva revolves around Corcept's Cushing's drug, Korlym, which was first approved in 2012. After the drug enjoyed several years of orphan drug exclusivity, Teva filed an ANDA in 2018 for a generic version, prompting a legal dispute. The dispute is regarding a couple of Corcept's key patents, particularly U.S. Patents 10,195,214 and 10,842,800, that cover methods of safely administering Korlym with CYP3A4 inhibitors. In late De ...